Does Oral Propranolol Accelerate Labor Induction/Augmentation With Oxytocin in Nulliparous Women in Abakaliki?
Overview
Labour is usually physiologic, spontaneous and progressive, but occasionally, there may be the need for induction or augmentation of labour especially in nulliparous women, who are at increased risk of dysfunctional labour. Oxytocin traditionally has been used for induction and augmentation of labour however prolonged labour continued to occur with attendant sequelae. Newer agents like propranolol, with minimal to no maternal and fetal adverse effects in labour have been shown to decreases the duration of labour when used in synergy with oxytocin. However, the paucity of information on the use of propranolol in labour.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: April 30, 2021
Detailed Description
ABSTRACT Background: Labour is usually physiologic, spontaneous and progressive, but occasionally, there may be the need for induction or augmentation of labour especially in nulliparous women, who are at increased risk of dysfunctional labour. Oxytocin traditionally has been used for induction and augmentation of labour however prolonged labour continued to occur with attendant sequelae. Newer agents like propranolol, with minimal to no maternal and fetal adverse effects in labour have been shown to decreases the duration of labour when used in synergy with oxytocin. However, the paucity of information on the use of propranolol in labour. Methodology: This research was a superiority open labelled randomized controlled trial that involved only nulliparous women who met the inclusion criteria and gave consent to the study. There was daily recruitment of participants. Randomization was by utilizing computer-generated numbers from a pool of 110 participants divided into A and B. Group A received 20 mg of oral propranolol before initiation of oxytocin titration. Group B received only oxytocin titration. Partograph was used to monitor their labour. Analysis: Absolute and relative frequencies of categorical variables, mean, range and standard deviation of continuous variables were calculated. Continuous variables were analyzed using students t-test while chi-square (χ2) test was used for categorical variables. A P-value of <0.05 was considered significant. Keywords: Propranolol, Labour, Induction, Augmentation, Nullipara
Interventions
- Drug: 20mg oral propranolol and oxytocin
- Participants will receive 20mg of oral propranolol 10minutes prior to initiation of augmentation or induction of labor with oxytocin
- Drug: Oxytocin only
- Participants will have outright augmentation or induction of labor with oxytocin
Arms, Groups and Cohorts
- Active Comparator: PROPRANOLOL GROUP
- Participants will receive 20mg of oral propranolol 10 minutes prior to initiation of augmentation or induction of labor with oxytocin
- Placebo Comparator: OXYTOCIN ONLY GROUP
- Participants had outright augmentation or induction of labor with oxytocin only
Clinical Trial Outcome Measures
Primary Measures
- Induction/Augmentation delivery intervals at delivery
- Time Frame: Time frame in minutes from the onset of initiation of Oxytocin to the delivery of the placenta
- Labor acceleration at delivery
Secondary Measures
- Maternal Blood pressure change in mmgh
- Time Frame: Change over 30 minutes
- Maternal Blood pressure is checked prior to initiation of oxytocin and 30 minutes after initiation of oxytocin. the difference is noted
- Fetal heart rate change in seconds
- Time Frame: Change over 30 minutes
- Fetal heart rate is checked prior to initiation of oxytocin and 30 minutes after initiation of oxytocin. the difference is noted
Participating in This Clinical Trial
Inclusion Criteria
1. Nulliparous women selected for induction or augmentation of labour 2. Term pregnancy selected for induction or augmentation of labour 3. Normal singleton pregnancies with cephalic presenting foetuses. 4. Those who gave their consent. Exclusion Criteria:
1. Co-existing medical illnesses such as diabetes mellitus, cardiac disease, haemoglobinopathies, renal diseases, hypertensive disease, Bronchial asthma, 2. Women currently taking Propranolol or a chronic beta-blocker use 3. Contraindications to labour or vaginal delivery 4. Multiple gestations 5. Preterm labour 6. Chorioamnionitis 7. Known fetal anomalies 8. Abnormal fetal presentation. 9. Antepartum haemorrhage. 10. Contraindication to induction and augmentation of labour 11. Multi-party 12. Known allergy to propranolol
Gender Eligibility: Female
Minimum Age: 16 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Darlington-Peter Chibuzor Ugoji
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Darlington-Peter Chibuzor Ugoji, Principal Investigator – Alex Ekwueme Federal University Teaching Hospital
- Overall Official(s)
- UGOJI DR DARLINGTON-PETER, PART 1, Principal Investigator, ALEX EKWUEME FEDERAL UNIVERSITY TEACHING HOSPITAL, ABAKALIKI, EBONYI STATE, NIGERIA
References
Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med. 2006 Apr 20;354(16):1698-705. doi: 10.1056/NEJMoa055119.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.